• Something wrong with this record ?

Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

T. Yanagisawa, M. Schmidinger, T. Kawada, K. Bekku, T. Kimura, SF. Shariat

. 2023 ; 9 (2) : 275-277. [pub] 20230210

Language English Country Netherlands

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc23010673

Immune checkpoint inhibitors (ICIs) have led to substantial changes in systemic treatment for metastatic renal cell carcinoma (mRCC). For patients whose metastases respond to upfront ICI therapy, deferred cytoreductive nephrectomy (CN) may confer a survival advantage. Further data from ongoing trials are awaited regarding the role of deferred versus immediate CN for mRCC in the ICI era. PATIENT SUMMARY: The first-line treatment currently recommended for kidney cancer that has spread to other sites is immunotherapy. For patients who experience a good response to this treatment, surgical kidney removal to control the primary tumor may have a survival benefit. More evidence from clinical trials is needed to confirm the efficacy of this approach.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010673
003      
CZ-PrNML
005      
20230801132558.0
007      
ta
008      
230718s2023 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.euf.2023.01.022 $2 doi
035    __
$a (PubMed)36775716
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Yanagisawa, Takafumi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
245    10
$a Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma / $c T. Yanagisawa, M. Schmidinger, T. Kawada, K. Bekku, T. Kimura, SF. Shariat
520    9_
$a Immune checkpoint inhibitors (ICIs) have led to substantial changes in systemic treatment for metastatic renal cell carcinoma (mRCC). For patients whose metastases respond to upfront ICI therapy, deferred cytoreductive nephrectomy (CN) may confer a survival advantage. Further data from ongoing trials are awaited regarding the role of deferred versus immediate CN for mRCC in the ICI era. PATIENT SUMMARY: The first-line treatment currently recommended for kidney cancer that has spread to other sites is immunotherapy. For patients who experience a good response to this treatment, surgical kidney removal to control the primary tumor may have a survival benefit. More evidence from clinical trials is needed to confirm the efficacy of this approach.
650    _2
$a lidé $7 D006801
650    12
$a karcinom z renálních buněk $x farmakoterapie $x chirurgie $7 D002292
650    12
$a nádory ledvin $x farmakoterapie $x chirurgie $x patologie $7 D007680
650    _2
$a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
650    _2
$a nefrektomie $7 D009392
650    _2
$a cytoredukční chirurgie $7 D065426
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Schmidinger, Manuela $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: manuela.schmidinger@meduniwien.ac.at
700    1_
$a Kawada, Tatsushi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
700    1_
$a Bekku, Kensuke $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
700    1_
$a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, The University of Jordan, Amman, Jordan; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia; Department of Urology, Weill Cornell Medical College, New York, NY, USA; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
773    0_
$w MED00193513 $t European urology focus $x 2405-4569 $g Roč. 9, č. 2 (2023), s. 275-277
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36775716 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132555 $b ABA008
999    __
$a ok $b bmc $g 1963244 $s 1196938
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 9 $c 2 $d 275-277 $e 20230210 $i 2405-4569 $m European urology focus $n Eur Urol Focus $x MED00193513
LZP    __
$a Pubmed-20230718
Back

Find record

Citation metrics

Archiving options